Nama's AI scorecard currently rates Rapport Therapeutics Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does RAPP report earnings?

Rapport Therapeutics's next scheduled report is on Mar 9, 2027. Analysts expect EPS of -$1.17.

What is the RAPP price target?

The median analyst price target from 14 analysts is $67.00, with a range of $50.00 – $91.00.

Is RAPP Shariah compliant?

Nama's AAOIFI-style screen reads Rapport Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Rapport Therapeutics (RAPP)

Healthcare · Biotechnology · NASDAQ

Rapport Therapeutics (RAPP) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $1.45B and a free-cash-flow yield of -9.2%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Middle · +21.7% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-53.8%

How far the last close sits under the highest price of the past five years.

Market cap	$1.45B
Trailing P/E	—
Price / book	2.8
Price / sales	67.9
FCF yield	-9.2%
Dividend yield	—
Gross margin	-109.4%
Operating margin	-767.6%
Net margin	0.0%
Revenue growth (YoY)	—
Revenue growth (3-yr annual)	—
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

RAPP earnings

Next report: Mar 9, 2027 (Q4 2026, EPS estimate -$1.17). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.84	-$1.22	+31.1%	$0
Q2 2026	Aug 5, 2026	-$1.19	-$0.99	-20.2%	$0
Q1 2026	May 7, 2026	-$0.42	-$0.71	+40.9%	$20.00M
Q4 2025	Mar 10, 2026	-$0.72	-$0.67	-7.5%	$0

RAPP analyst price target

Median target $67.00 from 14 analysts, ranging $50.00 – $91.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live RAPP data on Nama Insights →

RAPP FAQ

Is RAPP a buy?: Nama's AI scorecard currently rates Rapport Therapeutics Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does RAPP report earnings?: Rapport Therapeutics's next scheduled report is on Mar 9, 2027. Analysts expect EPS of -$1.17.
What is the RAPP price target?: The median analyst price target from 14 analysts is $67.00, with a range of $50.00 – $91.00.
Is RAPP Shariah compliant?: Nama's AAOIFI-style screen reads Rapport Therapeutics as Not Shariah Compliant. At least one of the three ratios or the industry test failed.